[Arf6, RalA and BIRC5 protein expression in non small cell lung cancer]

Area of Science:

• Molecular Oncopathology
• Cancer Signaling Pathways
• Biomarker Discovery

Background:

• Tumor marker expression patterns are crucial for understanding cancer progression.
• The Ras-Ral associated signal transduction pathway plays a role in various cancers.
• Identifying reliable biomarkers for non-small cell lung cancer (NSCLC) is essential for personalized treatment.

Purpose of the Study:

• To analyze the expression patterns of Arf6, RalA, and BIRC5 proteins in NSCLC.
• To correlate these expression patterns with clinical criteria and patient outcomes.
• To investigate the role of these proteins in the Ras-Ral pathway in NSCLC pathogenesis.

Main Methods:

• Western-blot analysis and Reverse Transcription Polymerase Chain Reaction (RT-PCR) were used for protein and gene expression analysis.
• Expression levels of Arf6, RalA, and BIRC5 were quantified in 53 NSCLC samples and compared to normal tissue.
• Statistical analysis was performed to identify significant correlations between protein expression and clinical parameters.

Main Results:

• Arf6 protein expression was elevated in 55% of NSCLC tumors, particularly in squamous cell lung cancer.
• RalA protein expression was decreased in 64% of NSCLC tumors, correlating with the absence of metastases in squamous cell lung cancer.
• BIRC5 protein expression was elevated in 76% of squamous cell lung cancer samples, compared to 63% in adenocarcinoma samples.

Conclusions:

• Arf6, RalA, and BIRC5 exhibit altered expression patterns in NSCLC, suggesting their involvement in tumor progression.
• Specific expression changes in Arf6 and RalA correlate with clinical parameters like tumor stage and metastasis in squamous cell lung cancer.
• These proteins represent potential biomarkers for NSCLC, warranting further investigation for diagnostic and therapeutic applications.